UNLABELLED: 3'-Fluoro-3'-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the human equilibrative nucleoside transporter-1 (ENT1). ENT1 facilitates transport of FLT into cells and elevated levels of FLT are associated with both larger FLT-PET signals and increased response to nucleoside-based chemotherapies. FLT-PET is also used as a measure of tumor proliferation. The present study examined the extent to which ENT1 levels vary in a proliferation-dependent manner in tumor cells in vivo. METHODS: The human adenocarcinoma cell line A549 was used to establish tumor xenografts in nude mice. FLT uptake was measured in vivo using PET, and further examined ex vivo using autoradiography. FLT uptake patterns were compared to immunohistochemical (IHC) analysis of ENT1 and the proliferation markers Ki67 and BrdU. RESULTS: Regional differences in FLT uptake matched differences in IHC proliferation markers. All cells stained for ENT1, but the staining intensity was twice as high for Ki67(+) cells than for Ki67(-) cells. CONCLUSIONS: Under in vivo conditions, proliferating regions of tumors show increased FLT uptake and higher ENT1 levels than nonproliferating tumor regions.
UNLABELLED: 3'-Fluoro-3'-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the humanequilibrative nucleoside transporter-1 (ENT1). ENT1 facilitates transport of FLT into cells and elevated levels of FLT are associated with both larger FLT-PET signals and increased response to nucleoside-based chemotherapies. FLT-PET is also used as a measure of tumor proliferation. The present study examined the extent to which ENT1 levels vary in a proliferation-dependent manner in tumor cells in vivo. METHODS: The humanadenocarcinoma cell line A549 was used to establish tumor xenografts in nude mice. FLT uptake was measured in vivo using PET, and further examined ex vivo using autoradiography. FLT uptake patterns were compared to immunohistochemical (IHC) analysis of ENT1 and the proliferation markers Ki67 and BrdU. RESULTS: Regional differences in FLT uptake matched differences in IHC proliferation markers. All cells stained for ENT1, but the staining intensity was twice as high for Ki67(+) cells than for Ki67(-) cells. CONCLUSIONS: Under in vivo conditions, proliferating regions of tumors show increased FLT uptake and higher ENT1 levels than nonproliferating tumor regions.
Authors: Tal Yardeni; Michael Eckhaus; H Douglas Morris; Marjan Huizing; Shelley Hoogstraten-Miller Journal: Lab Anim (NY) Date: 2011-05 Impact factor: 12.625
Authors: Robert J Paproski; Amy M L Ng; Sylvia Y M Yao; Kathryn Graham; James D Young; Carol E Cass Journal: Mol Pharmacol Date: 2008-07-31 Impact factor: 4.436
Authors: Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Meg Perumal; Radhakrishna G Pillai; Henryk Barthel; Julius Leyton; John R Latigo; Martin Forster; Fraser Mitchell; Ann L Jackman; Eric O Aboagye Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers Journal: Br J Cancer Date: 2005-12-12 Impact factor: 7.640
Authors: Laura L Boles Ponto; Susan Walsh; Jiangeng Huang; Christine Mundt; Katherine Thede-Reynolds; G Leonard Watkins; John Sunderland; Michael Acevedo; Maureen Donovan Journal: AAPS J Date: 2017-12-07 Impact factor: 4.009
Authors: David A Plotnik; Stephen Wu; Geoffrey R Linn; Franco Chi Tat Yip; Natacha Lou Comandante; Kenneth A Krohn; Jun Toyohara; Jeffrey L Schwartz Journal: Nucl Med Biol Date: 2014-12-06 Impact factor: 2.408